All
Events
News
Meet Us at ASM Microbe in Atlanta June 7-11, 2018
First Light Diagnostics (formerly First Light Biosciences) would like you to join us in Atlanta for ASM Microbe 2018. We invite you to learn more about our latest developments in Clostridium diffcile testing and other advancements in rapid diagnostic testing where First Light aims to advance health care practices to improve detection of deadly hospital associated infections….
Join Us at ECCMID in Madrid April 21-24, 2018
First Light Diagnostics (formerly First Light Biosciences) welcomes you to join us at the 28th Annual ECCMID Congress in Madrid, April 21-24, 2018. First Light will be presenting our latest work highlighting our latest the advances in the detection of Clostridium difficile testing. CEO Don Straus will be in attendance and welcomes you to learn…
Updated IDSA/SHEA Clinical Practice Guidelines for Clostridium difficile Infection Recognizes the Importance of Toxin Testing.
The updated Clinical Practice Guidelines for Clostridium difficile from The Infectious Disease Society of America (IDSA) and the Society of Healthcare Epidemiology of America (SHEA) have been recently published in the journal Clinical Infectious Diseases. The new recommendations emphasize the importance of toxin tests in accurately identifying Clostridium difficile infection (CDI) and suggest that this type of testing is…
New Additions to First Light Management Team and Board of Directors
BEDFORD, Mass., November 2, 2017 – First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAIs) announced today two new additions to the First Light team. William Moffitt joins the First Light Diagnostics board of directors as its chairman. Mr….
First Light Biosciences Selected as a Semifinalist in the First Phase of the Antimicrobial Resistance Diagnostic Challenge
Bedford, MA (March 2017) — First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) today announced they had been selected as a semifinalist and awarded a $50,000 prize in the first phase (Step 1) of the Antimicrobial Resistance Diagnostic…
Don Straus Interviewed by BBC as Part of Antibiotic Resistance Program
Bedford, MA (October 2016) – First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) today announced their participation in a BBC interview. Speaking to the BBC, Don Straus, CEO of First Light Biosciences, discussed the challenges currently faced by hospitals as it relates…
First Light Biosciences Recognized as one of two Massachusetts Companies to win a Mass Life Science Center Accelerator loan
Bedford, MA (May 2016) – First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) today announced its selection by the Massachusetts Life Sciences Center (MLSC) to receive $750,000 in Accelerator loan financing as a promising early stage company. According to the MLSC press…
First Light Biosciences Selected by Strategic News Service to be Featured at the 2016 Future in Review Conference.
Bedford, MA (February 2016) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today its selection by the Strategic News Service as a 2016 FiReStarter company to be featured at the 14th annual Future in Review (FiRe) conference. FiRe 2016 will…
First Light Signs Contract with the Biomedical Advanced Research and Development Authority
Bedford, MA (October 2015) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today a contract with the Biomedical Advanced Research and Development Authority to develop rapid, sensitive, and easy-to-use anthrax tests. The contract supports the project with $5.5 million over…
First Light Closes $3.5M Series A Financing
Bedford, MA (September 2015) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today closure of $3.5 Million in series A financing. The financing will be used to continue developing tests to rapidly detect hospital infections and determine their susceptibility to…